Organic anion transporting polypeptide 2B1 - More than a glass-full of drug interactions.

Autor: McFeely SJ; School of Pharmacy, Department of Pharmaceutics, University of Washington, Seattle, WA, USA., Wu L; School of Pharmacy, Department of Pharmaceutics, University of Washington, Seattle, WA, USA., Ritchie TK; School of Pharmacy, Department of Pharmaceutics, University of Washington, Seattle, WA, USA., Unadkat J; School of Pharmacy, Department of Pharmaceutics, University of Washington, Seattle, WA, USA. Electronic address: jash@uw.edu.
Jazyk: angličtina
Zdroj: Pharmacology & therapeutics [Pharmacol Ther] 2019 Apr; Vol. 196, pp. 204-215. Date of Electronic Publication: 2018 Dec 14.
DOI: 10.1016/j.pharmthera.2018.12.009
Abstrakt: The importance of uptake transporters in determining drug disposition is increasingly appreciated. While the focus of regulatory agencies worldwide has been on the hepatic organic anion transporting polypeptides (OATPs)-1B1 and-1B3, there is another isoform of the OATP sub-family, OATP2B1, which should be considered equally relevant. Unlike the other members of the OATP sub-family, OATP2B1 is expressed in multiple organs in humans, including in the intestine and the liver. Similar to other OATPs, OATP2B1 mediates the hepatic and intestinal uptake of many drugs and endogenous compounds. The importance of OATP2B1 in the disposition of many drugs is highlighted by the growing recognition of its role in significant in vivo drug-drug or food-drug interactions. The dramatic changes in drug exposure attributable to inhibition of OATP2B1 highlight the importance of developing a better understanding of the clinical role of OATP2B1. This review aims to provide a thorough summary of the current understanding of the pharmacogenetics, regulation, expression and abundance of OATP2B1 in humans, as well as its clinical relevance in drug-drug and food-drug interactions.
(Copyright © 2018 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: